Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Diseaseinvestors.comThe drug technically missed the study's primary goal. But there's still promise it could work in specific patients.
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefitsbenzinga.comProthena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024investorplace.comPRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Wininvestors.comAn FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024investorplace.comPRTA stock results show that Prothena Corp missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setbackinvestors.comThe FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
